Literature DB >> 2676266

The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group.

J L Probstfield1, W B Applegate, N O Borhani, J D Curb, J A Cutler, B R Davis, C D Furberg, C M Hawkins, E Lakatos, L B Page.   

Abstract

The Systolic Hypertension in the Elderly Program (SHEP) is a randomized double-blind placebo-controlled trial to determine if antihypertensive treatment of isolated systolic hypertension (ISH) [systolic blood pressure (SBP) greater than or equal to 160 mmHg, diastolic blood pressure (DBP) less than 90 mmHg] reduces the 5 year incidence of fatal and nonfatal stroke. Between March 1, 1985 and January 15, 1988, 4736 persons (target 4800) with ISH, age 60 years and over, were enrolled. Potential participants met blood pressure (BP) and age criteria. Those on antihypertensive medication prior to enrollment without documented diastolic hypertension had their medication tapered and discontinued, and then met BP criteria (33% of cohort). Stepped-care therapy with chlorthalidone and atenolol (alternative, reserpine) or matching placebos was initiated as first and second steps. At baseline the trial population was 43.1% male, 56.9% female; 13.9% black, 86.1% non-black. Also, the mean age was 71.6 years; the mean SBP was 170.3 mmHg and the mean DBP was 76.6 mmHg; 59.8% had codeable resting electrocardiographic abnormalities. The trial is now in follow-up phase with scheduled termination in 1991.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2676266     DOI: 10.3109/10641968909035386

Source DB:  PubMed          Journal:  Clin Exp Hypertens A        ISSN: 0730-0077


  12 in total

Review 1.  A Comparison of Vasodilating and Non-vasodilating Beta-Blockers and Their Effects on Cardiometabolic Risk.

Authors:  Icilma V Fergus; Kenneth L Connell; Keith C Ferdinand
Journal:  Curr Cardiol Rep       Date:  2015-06       Impact factor: 2.931

2.  Pathological correlates of white matter hyperintensities on magnetic resonance imaging.

Authors:  Yong Soo Shim; Dong-Won Yang; Catherine M Roe; Mary A Coats; Tammie L Benzinger; Chengjie Xiong; James E Galvin; Nigel J Cairns; John C Morris
Journal:  Dement Geriatr Cogn Disord       Date:  2014-11-08       Impact factor: 2.959

Review 3.  Blood pressure-lowering efficacy of reserpine for primary hypertension.

Authors:  Sandy D Shamon; Marco I Perez
Journal:  Cochrane Database Syst Rev       Date:  2016-12-21

Review 4.  Promoting successful cognitive aging: a comprehensive review.

Authors:  Kirk R Daffner
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

5.  Screening for hypertension among older adults: a primary care "high risk" approach.

Authors:  Jacob John; Jayaprakash Muliyil; Vinohar Balraj
Journal:  Indian J Community Med       Date:  2010-01

6.  Analysis of pharmacotherapy of hypertension in out-patients.

Authors:  J Vlcek; M Tesarová; Z Fendrich
Journal:  Pharm World Sci       Date:  1995-05-26

7.  Blood Pressure Measurement in SPRINT (Systolic Blood Pressure Intervention Trial).

Authors:  Karen C Johnson; Paul K Whelton; William C Cushman; Jeffrey A Cutler; Gregory W Evans; Joni K Snyder; Walter T Ambrosius; Srinivasan Beddhu; Alfred K Cheung; Lawrence J Fine; Cora E Lewis; Mahboob Rahman; David M Reboussin; Michael V Rocco; Suzanne Oparil; Jackson T Wright
Journal:  Hypertension       Date:  2018-03-12       Impact factor: 10.190

8.  The impact of an individualized risk-adjusted approach on hypertension treatment in primary care.

Authors:  Stefan Zechmann; Oliver Senn; Fabio Valeri; Stefan Neuner-Jehle; Thomas Rosemann; Sima Djalali
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-01-06       Impact factor: 3.738

Review 9.  Pharmacotherapy for mild hypertension.

Authors:  Diana Diao; James M Wright; David K Cundiff; Francois Gueyffier
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

10.  Pharmacotherapy for hypertension in adults 60 years or older.

Authors:  Vijaya M Musini; Aaron M Tejani; Ken Bassett; Lorri Puil; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2019-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.